Transcend Capital Advisors, LLC Novavax Inc Transaction History

Transcend Capital Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 12, 2022	BUY	$36.28 - $75.29 $149,401 - $310,044	4,118 New	4,118 $212,000
Q1 2022 Apr 20, 2022	SELL	$69.73 - $142.9 $155,009 - $317,666	-2,223 Closed	0 $0
Q4 2021 Jan 20, 2022	BUY	$134.56 - $217.97 $79,121 - $128,166	588 Added 35.96%	2,223 $318,000
Q3 2021 Nov 04, 2021	SELL	$177.8 - $270.58 $54,229 - $82,526	-305 Reduced 15.72%	1,635 $221,000
Q2 2021 Aug 13, 2021	SELL	$121.0 - $257.67 $11,495 - $24,478	-95 Reduced 4.67%	1,940 $412,000
Q1 2021 May 12, 2021	SELL	$112.98 - $319.93 $74,566 - $211,153	-660 Reduced 24.49%	2,035 $369,000
Q4 2020 Feb 12, 2021	BUY	$78.74 - $139.5 $212,204 - $375,952	2,695 New	2,695 $301,000

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $662M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Transcend Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Transcend Capital Advisors, LLC with notifications on news.